Chemomab Therapeutics Ltd. CMMB
1.18 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
1.35 +0.17 +14.41%
After hours · Nov 3, 4:00 PM ET
1.16 Day range 1.33
0.92 52-week range 2.99
- YTD
- -28.48%
- 1 year
- -57.86%
- Market cap
- 9.50M
- EPS (ttm)
- -1.05
- Shares out
- 18.86M
- Forward P/E
- -41.25
- YTD return
- -28.48%
- 1-year return
- -57.86%
- Volume
- 38.89K
- Avg volume
- 99.64K
- Open
- 1.33
- Previous close
- 1.18
- Day's range
- 1.16 – 1.33
- 52-week range
- 0.92 – 2.99
- Beta
- 0.30
- Price target
- 8.00 (+578.0%)
- Earnings date
- Aug 21, 2024
2Y -4.59 (-79.69%)
Key statistics
- Enterprise value
- 447.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.36M
- Total cash
- 12.73M
- Total debt
- 360.00K
- Return on equity
- -93.80%
- Short % of float
- 0.87%
- 50-day average
- 1.57
- 200-day average
- 1.23
Analyst view
Price target (mean) 8.00 +578.0% upside
Now 1.18
- Target (low)
- 4.00
- Target (mean)
- 8.00
- Target (high)
- 11.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 21, 2024
Expected Aug 21, 2024. Consensus EPS estimate -0.01.
Financials — quick view
CMMB Revenue — quarterly 0
CMMB Net income — quarterly -2.17M
CMMB EPS — quarterly -0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 21, 2024 | Jun 1, 2024 | -0.20 | -0.26 | -0.06 | -30.00% |
| Aug 21, 2024 | Jun 1, 2024 | -0.20 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.20 | -0.28 | -0.08 | -40.00% |
| May 9, 2024 | Mar 1, 2024 | -0.20 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.40 | -0.26 | +0.14 | +35.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 13, 2024 | Maxim Group | init | — | Buy |
| May 6, 2024 | Oppenheimer | up | Perform | Outperform |
| Mar 8, 2024 | Oppenheimer | main | Perform | Perform |
| Oct 6, 2023 | Roth MKM | init | — | Buy |
| Jun 7, 2023 | Oppenheimer | down | Outperform | Perform |
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- chemomab.com
News
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Monday's After-Market Session 
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference 
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate 
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - 12 Health Care Stocks Moving In Wednesday's Intraday Session
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Chemomab Therapeutics, Scipher Medicine Strike All-Stock Merger Agreement; Combined Entity Expected To Operate Under Scipher Medicine Name, SCIP Ticker On Nasdaq
Your note
Sign in to keep a note on CMMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MOR GEORGE ADI | Officer and Director | Sale | Jan 2, 2023 | 0 |
| ORBIMED ISRAEL GP LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 2, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 9.23% | 1,741,273 | 2.87M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 6.44% | 1,214,575 | 2.00M | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 4.29% | 809,717 | 1.34M | Sep 29, 2024 |
| Morgan Stanley | 2.13% | 402,272 | 663.75K | Sep 29, 2024 |
| Ikarian Capital, LLC | 1.13% | 213,392 | 352.10K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.21% | 39,939 | 65.90K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 200 | 329 | Jun 29, 2024 |